Nineteen uncontrolled studies (895 participants) were included in the review. Median/mean length of follow-up ranged from 14 to 64 months.
Perioperative mortality rates associated with treatment ranged from zero to 10% (16 studies). Between zero and 70% of patients suffered grade I morbidity (12 studies), 1% to 50% suffered grade II morbidity (12 studies), zero to 40% suffered grade III morbidity (13 studies) and zero to 15% suffered grade IV morbidity (14 studies). Common postoperative complications included ileus, anastomotic leakage, bleeding, wound infection, toxicity, pleural effusion, infections, fistula, transient hepatitis and thrombocytopenia. Median length of hospital stay ranged from eight to 25 days (13 studies).
Median/mean disease-free survival ranged from 10 to 57 months (16 studies), median overall survival ranged from 24 to 64 months (13 studies), median overall survival for patients with an optimal cytoreduction ranged from 26 to 66 months (10 studies), overall three-year survival rate ranged from 35 to 63% (seven studies) and overall five-year survival rate ranged from 12 to 66% (nine studies).